Clinical • Trial completion date • Trial primary completion date • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • MUC16 (Mucin 16, Cell Surface Associated)
|
PD-L1 expression • TP53 mutation • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA